3 of the Best Growth Stocks to Buy for Less Than $100 Right Now

The article identifies Netflix, Uber and Novo Nordisk as long-term value opportunities after double-digit share-price declines, citing discounted valuations and durable growth prospects. Netflix is down 17% this year and trades at 25x trailing earnings; Uber is down about 18% over the past year but trades at 17x earnings after generating more than $55B in trailing-12-month revenue and $9.6B in net income. Novo Nordisk trades near $47 at 11x earnings with a roughly 3.9% yield, with the investment case hinging on recovery potential in the competitive GLP-1 drug market.

Analysis

The source’s quoted prices, earnings multiples, and Uber net-income figure appear internally inconsistent with reported-company financials, so this is not independently actionable as a valuation screen. Before deploying capital, reconcile split-adjusted prices, GAAP versus adjusted EPS, and whether Uber’s income includes investment revaluations; those distinctions materially change the apparent discounts.

NVO is the clearest relative-value setup, but the market is pricing a durable share-loss regime rather than a one-quarter execution issue. A stabilization in prescription trends, manufacturing availability, or obesity-trial differentiation could drive both earnings-revision recovery and multiple expansion over 3-9 months; conversely, further U.S. price concessions or Lilly share gains would validate the discount. The second-order beneficiary of sustained GLP-1 pricing competition is LLY, whose premium multiple remains vulnerable if category growth shifts from supply-constrained to price-competitive.

UBER’s near-term earnings sensitivity remains more tied to mobility bookings, incentive intensity, and insurance costs than robotaxi headlines. Autonomous partnerships can improve supply economics, but they also create a longer-term risk that the platform becomes a lower-take-rate demand aggregator; the key 6-18 month question is whether Uber retains customer ownership and pricing power. NFLX requires evidence that advertising and live-content monetization exceed rising sports-rights/content amortization before assuming its growth multiple can re-rate.

Key Decisions for Investors

• Initiate a 3-6 month long NVO / short LLY pair only after confirming weekly prescription-share stabilization and no further NVO guidance cut; target 15-20% relative upside with a 7% relative stop if Lilly continues to gain share through the next data point.
• Keep UBER on a post-earnings watch rather than buy solely on the cited P/E. Go long only if gross bookings growth holds while adjusted EBITDA margin expands despite insurance and incentives; use a 10% stop, as a take-rate decline or elevated incentives would undermine the thesis.
• For NFLX, wait for the next subscriber, ad-revenue, and free-cash-flow guide before adding exposure. A long position is justified only if ad-tier monetization offsets incremental live-sports/content commitments; otherwise prefer neutral exposure because rights-cost escalation can compress FCF conversion before revenue benefits appear.
• Monitor LLY for downside hedging: if GLP-1 category pricing deteriorates or NVO demonstrates competitive efficacy and supply recovery, buy 6-9 month LLY puts or reduce overweight exposure; the risk is multiple compression rather than an immediate volume collapse.